The VeriStrat® test (VS) is a blood-based assay that predicts a patient's response to therapy by analyzing eight features in a spectrum obtained from matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) analysis of human serum and plasma. In a recent analysis of the INSIGHT clinical trial (NCT03289780), it was found that the VS labels, VS Good and VS Poor, can effectively predict the responsiveness of non-small cell lung cancer (NSCLC) patients to immune checkpoint inhibitor (ICI) therapy. However, while VS measures the intensities of spectral features using MALDI-TOF analysis, the specific proteoforms underlying these features have not been comprehensively identified. The objective of this study was to identify the proteoforms that are measured by VS. To resolve the features obtained from the low-resolution MALDI-TOF procedure used to acquire mass spectra for VS DeepMALDI® analysis of serum was employed. This technique allowed for the identification of finer peaks within these features. Additionally, a combination of reversed-phase fractionation and liquid chromatography-tandem mass spectrometry (LC-MS/MS) was then used to identify the proteoforms associated with these peaks. The analysis revealed that the primary constituents of the spectrum measured by VS are serum amyloid A1, serum amyloid A2, serum amyloid A4, C-reactive protein, and beta-2 microglobulin. Proteoforms involved in host immunity were identified as significant components of these features. This newly acquired information improves our understanding of how VS can accurately predict patient response to therapy. It opens up additional studies that can expand our understanding even further.
17 July 2025 in The Astrophysical Journal Supplement Series
The Simons Observatory (SO) is a ground-based cosmic microwave background (CMB) survey experiment that currently consists of three 0.42 m small-aperture telescopes and one 6 m large-aperture telescope (LAT), located at an elevation of 5200 m in the Atacama Desert in Chile. At the LAT’s focal plane, SO will install >62,000 transition-edge sensor detectors across 13 optics tubes (OTs) within the Large Aperture Telescope Receiver (LATR), the largest cryogenic camera ever built to observe the CMB. Here we report on the validation of the LATR in the laboratory and the subsequent dark testing and validation within the LAT. We show that the LATR meets cryogenic, optical, and detector specifications required for high-sensitivity measurements of the CMB. At the time of writing, the LATR is installed in the LAT with six OTs (corresponding to >31,000 detectors), and the LAT mirrors and remaining seven OTs are undergoing development.